drugset
drugset / Trial / NCT04594928

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

NCT04594928 ↗

Phase 1 Completed 30 enrolled Lakefront Biotherapeutics NV
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this research study is to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG3667 in multiple daily oral doses in subjects with moderate to severe plaque psoriasis.

Timeline

Start
2020-10-19
Primary completion
2021-05-04
Completion
2021-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG3667 Small molecule — Oral

Indications

psoriasis